Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder. Fair value range: low $176, high $337, with mid-point at $255.
Этот отчёт ещё не переведён. Обновите страницу через несколько минут, когда очередь переводов его обработает.
§1 Краткое резюме
Premium quality compounder with a wide competitive moat.
Reverse DCF implies ~20% perpetual growth required at current $450 price.
Intrinsic valuation models anchor at $254.67, signaling a massive premium.
Sell recommendation driven by extreme valuation disconnect, not business quality.
Fair value
$255
Margin of safety
-76.7%
Confidence
87/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$450.06Price
Low $175.51
Mid $254.67
High $336.56
Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder.
Massive installed base of da
Massive installed base of da Vinci systems
High switching costs for hospitals
High switching costs for hospitals and surgeons
Cycle upside
Post-pandemic procedure backlog clearance drives elevated system utilization and instrument consumption.
Each scenario for ISRG (ISRG) carries a five-year price target, an explicit set of assumptions (growth, terminal multiple, margin path), and a probability weight calibrated against current visibility.
Probability weights start from a 25/50/25 default and are asymmetry-adjusted: when downside risk is elevated, base + bear gain weight; when visibility is high (long RPO, multi-year contracts), bull and base both gain.
Expected return is the probability-weighted average of the three scenario returns. The expected-value table reports the weighted price, weighted return, and asymmetry to help the reader compare risk-reward against the rating band.
When our composite fair value differs from private calibration references by more than 30%, the calibration-divergence diagnostic is run to identify which assumptions drive the gap; the result is summarised in the parent valuation surface.
FAQ
ISRG — frequently asked questions
Based on our latest analysis, ISRG looks meaningfully overvalued. The current price is $450 versus a composite fair-value midpoint of $255 (range $176–$337), which implies roughly 43.4% downside to the midpoint.
Our composite fair-value range for ISRG is $176–$337, with a midpoint of $255. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for ISRG's archetype.
Our current rating for ISRG is Sell with a confidence score of 87/100. Sell. The 56% divergence from internal valuation cross-checks signals heavy market premium; intrinsic baseline valuation is $254.67. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for ISRG are: Medtronic/J&J Capture 30% Market Share; Severe Hospital Capex Freeze; New Modality Disruption. The single biggest risk is Medtronic/J&J Capture 30% Market Share: Competitors successfully disrupt the monopoly, forcing severe pricing pressure on systems and instruments.
Our current rating for ISRG is Sell, issued with a confidence score of 87/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($176–$337) versus the current price of $450.
ISRG is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ISRG.
